GSK

GSK to Acquire RAPT Therapeutics for $2.2 Billion

GSK announced a definitive agreement to acquire RAPT Therapeutics for $2.2 billion, gaining rights to ozureprubart, a next-generation treatment that could protect food allergy patients.

Bioelectronic Medicines: A New Type of Personalization

GSK Sued by Former Private Investigators

GSK and Fimbrion Link on UTI Drug

Teva Launches Generic Epzicom Tablets in US

GSK’s Witty for Responsible Pricing

Walmsley Named New CEO of GSK

GSK Divests Anesthetic Drugs to Aspen

Sanofi and Verily in Diabetes JV

Best Pharma Brands

GSK and Verily Life Sciences in Bioelectronics JV

GSK Plans £275 Million UK Investment

FDA Warns GSK on Contamination at UK Plant

Britain in Uncertainty

UK Drugs Industry Forms Brexit Steering Group

GSK Vaccines Head to Step Down

Novartis Splits Pharmaceutical Division

GSK Break-up “not Under Consideration”

GSK to Waive Patents in Poor Countries

Pfizer to Acquire Meningitis Vaccines From GSK

GSK Acquires GlycoVaxyn for $212 Million

Corruption Charges Against GSK Seen as Warning

GSK Faces Criminal Bribery Investigation in Poland

Amgen Ends Non-U.S. Co-Marketing Pact With GSK

GlaxoSmithKine Investigates Alleged Bribery in Iraq

GSK Combined Melanoma Treatment Delayed in Europe

GlaxoSmithKline Offer lifts Indian Stakeholding to 75%

Facing Fines, Glaxo SmithKline to Stop Drug Promotion Excesses

Cameron Raises GSK’s Problems as CEO Joins Him On China Visit

Glaxo SmithKline to Invest in Scottish Plant expansion

GSK Puts Lucozade and Ribena Drink Brands up for Sale

UK Watchdog Accuses GSK Over 'Pay-for-delay' Drug Deals

GSK Plans $1 Million Prize to Jump-start "Electroceuticals"

Optimer Shares Rise After Report Names Glaxo, Cubist as Potential Buyers

GSK and J&J Lead Rivals in Drug Access for Poor